Loading…
Keros Therapeutics, Inc. is projected to rise to $11.51 by 2027, a +14% move from its current price of $10.07. KROS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $9.85 | $10.07 | $10.30 | +0.04% |
| Aug 4 | $9.76 | $10.08 | $10.40 | +0.07% |
| Aug 5 | $9.70 | $10.08 | $10.48 | +0.11% |
| Aug 6 | $9.64 | $10.08 | $10.55 | +0.15% |
| Aug 7 | $9.60 | $10.09 | $10.61 | +0.18% |
| Aug 8 | $9.55 | $10.09 | $10.66 | +0.22% |
| Aug 9 | $9.51 | $10.10 | $10.71 | +0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.51 | $10.10 | $10.71 | +0.26% |
| Week 2 | $9.31 | $10.12 | $11.01 | +0.52% |
| Week 3 | $9.16 | $10.15 | $11.25 | +0.78% |
| Week 4 | $9.04 | $10.17 | $11.46 | +1.04% |
| Week 5 | $8.93 | $10.20 | $11.65 | +1.30% |
| Week 6 | $8.84 | $10.23 | $11.83 | +1.56% |
| Week 7 | $8.76 | $10.25 | $12.00 | +1.82% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company in Healthcare that develops therapeutics to treat disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, a ligand trap that inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds.
Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Keros Therapeutics, Inc. (KROS) operates in the Healthcare sector as a clinical-stage biopharmaceutical company focused on therapies linked to transforming growth factor-beta signaling. The current price is $10.21 with a market capitalization of $202.07M, and the stock ranks 3648 by market cap.
The price remains near the 50-day simple moving average of $10.84 and below the 200-day moving average of $14.45, indicating a bearish near-term position. The stock trades within a 30-day range of $8.58 to $12.15, with a support at $9.93 and a resistance at $12.03. Annualized volatility is 50%.
Forecasts project a path from neutral in 2026 to bullish growth through 2050, with the 2026 average price at $10.21 and a max of $14.32, and longer-term averages rising to $77.08 by 2050 (ROI 655%).
A major floor 14.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.0% away) — a key level to hold.
The nearest ceiling, 19.5% above — a clean break opens room to run.
A major ceiling 26.6% above — clearing it would confirm fresh momentum.
Key KROS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KROS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.11 | Sell | $10.13 | Sell |
| MA 10 | $10.21 | Sell | $10.26 | Sell |
| MA 20 | $10.71 | Sell | $10.47 | Sell |
| MA 50 | $10.71 | Sell | $10.82 | Sell |
| MA 100 | $11.04 | Sell | $11.68 | Sell |
| MA 200 | $14.25 | Sell | $13.57 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.51 | Neutral |
| Stoch RSI (14) | 24.04 | Neutral |
| CCI (20) | -80.59 | Neutral |
| Williams %R (14) | -90.57 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -8.70 | Sell |
| Bollinger %B (20,2) | 0.25 | Neutral |
| Stochastic %K (14) | 9.43 | Buy |
| TRIX (15) | -0.19 | Sell |
| Awesome (5,34) | -0.59 | Sell |
| Ultimate (7,14,28) | 39.58 | Neutral |
| Momentum (10) | -0.57 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 10.05 | Buy |
| ADX (14) | 14.62 | Neutral |
| ATR (14) | 0.22 | Info |
The near-term technical picture is Bearish. The RSI(14) is 40, and the stock sits below the 200-day moving average while trading around the 50-day moving average of $10.84. Support is at $9.93 and resistance at $12.03, with a 30-day price range of $8.58–$12.15.
These factors reflect ongoing selling pressure, even as volatility remains elevated (annualized volatility 50%).
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.91 | $10.07 | $13.75 | 0% | Neutral | |
| $9.33 | $11.51 | $14.91 | +14% | Neutral | |
| $11.16 | $14.08 | $18.84 | +40% | Bullish | |
| $12.47 | $16.03 | $21.98 | +59% | Bullish | |
| $13.04 | $17.05 | $23.87 | +69% | Bullish | |
| $13.67 | $18.14 | $25.86 | +80% | Bullish | |
| $13.41 | $18.04 | $26.15 | +79% | Bullish | |
| $14.06 | $19.16 | $28.19 | +90% | Bullish | |
| $15.62 | $21.55 | $32.13 | +114% | Bullish | |
| $17.65 | $24.63 | $37.20 | +145% | Bullish | |
| $20.59 | $30.26 | $48.24 | +201% | Bullish | |
| $42.90 | $68.86 | $118.75 | +584% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $9.91 | $10.07 | $12.37 | +0.00% |
| September 2026 | $8.83 | $10.39 | $12.54 | +3.21% |
| October 2026 | $8.80 | $10.41 | $12.67 | +0.20% |
| November 2026 | $9.12 | $10.84 | $13.28 | +4.06% |
| December 2026 | $9.34 | $11.15 | $13.75 | +2.85% |
Click any year to see its month-by-month KROS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, KROS is projected to trade between $9.91 and $13.75, averaging $10.07 — a potential gain of 0% from today's $10.07. Price action looks broadly range-bound.
Keros Therapeutics, Inc.'s 2027 outlook centres on $11.51, within a $9.33 to $14.91 range. That is up +14% on the projected 2026 average. That marks a +14% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, KROS could reach as high as $18.84, with a base case around $14.08 and support toward $11.16 — roughly +40% from $10.07. Momentum favours further upside here.
Expect KROS to range from $12.47 to $21.98 through 2029. The $16.03 average target implies a +59% move from current prices. That is up +14% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The KROS price prediction for 2030 points to an average of $17.05 (low $13.04, high $23.87) — a potential gain of +69% on today's $10.07. Momentum favours further upside here.
In 2031, KROS is projected to trade between $13.67 and $25.86, averaging $18.14 — a potential gain of +80% from today's $10.07. That is up +6% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Keros Therapeutics, Inc.'s 2032 outlook centres on $18.04, within a $13.41 to $26.15 range. That is -1% versus the projected 2031 average. That marks a +79% change versus current levels. Momentum favours further upside here.
By 2033, KROS could reach as high as $28.19, with a base case around $19.16 and support toward $14.06 — roughly +90% from $10.07. Buyers look set to stay in control over this stretch.
Expect KROS to range from $15.62 to $32.13 through 2034. The $21.55 average target implies a +114% move from current prices. That is up +12% on the projected 2033 average. Momentum favours further upside here.
The KROS price prediction for 2035 points to an average of $24.63 (low $17.65, high $37.20) — a potential gain of +145% on today's $10.07. Buyers look set to stay in control over this stretch.
In 2040, KROS is projected to trade between $20.59 and $48.24, averaging $30.26 — a potential gain of +201% from today's $10.07. That is up +23% on the projected 2035 average. Momentum favours further upside here.
Keros Therapeutics, Inc.'s 2050 outlook centres on $68.86, within a $42.90 to $118.75 range. That is up +128% on the projected 2040 average. That marks a +584% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in KROS today (≈ 99.304866 KROS) could be worth
$6,837.73
+$5,837.73 (+584%) by 2050 · US Dollar
Based on the average projected KROS price of $68.86 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KROSwould be worth at today's price.
$1,000 invested in KROS on Jul 31, 2025 (≈ 69.832404 KROS) would be worth
$703.21
-$296.79 (-29.7%) today · 0.70× · US Dollar
Based on a KROS entry price of $14.32 vs. today's $10.07.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.06 | $1,000.99 | +0.1% |
| 1 month ago | $10.88 | $925.55 | -7.4% |
| 3 months ago | $11.49 | $876.41 | -12.4% |
| 6 months ago | $18.4 | $547.28 | -45.3% |
| 1 year ago | $14.32 | $703.21 | -29.7% |
| All time (5.0y) ago | $34.78 | $289.53 | -71.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KROS forecast.
Our base-case forecast reaches $20.00 around 2034.
Implied market cap at $20.00: $395.84M
The multi-year forecast shows a bullish trajectory after 2026, with the average price rising from $10.21 in 2026 to $18.19 in 2030 and then to $77.08 by 2050. The forecasted ROIs include 0% in 2026, 15.6% in 2027, 48.4% in 2028, 68.4% in 2029, 78.1% in 2030, 92.1% in 2031, 86.3% in 2032, 99.7% in 2033, 131.8% in 2034, 162.4% in 2035, 223.6% in 2040, and 655% in 2050. The 2050 maximum price is projected at $140.60.
These are estimates, not guarantees, and are subject to the usual risks associated with clinical-stage therapeutics and market conditions.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $18.19 with an ROI of 78.1%, and a range from a minimum of $13.57 to a maximum of $26.24.
Forecasts show a bullish long-term trajectory with the average price rising to $77.08 by 2050 and an ROI of 655%, but near-term sentiment is mixed (neutral to bearish in early years) and the stock carries high volatility (annualized volatility 50%).
Yes. The 2050 forecast lists a maximum price of $140.60, with earlier years showing lower maximums; the long-term potential could exceed $100 according to the projected path.
Current price is $10.21 and market capitalization is $202.07M.
The 30-day picture is Bearish, with RSI(14) at 40, SMA(50) at $10.84, SMA(200) at $14.45, a support level of $9.93, a resistance level of $12.03, and a 30-day price range of $8.58 to $12.15.
Keros Therapeutics, Inc. Community Discussion
0Share your Keros Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.